The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Thermo Fisher Launches Gibco CTS Compleo System to Automate Cell Therapy Manufacturing

Key Facts

1Thermo Fisher unveiled the Gibco CTS Compleo system to automate cell therapy manufacturing.

2The system aims to improve efficiency and consistency as demand rises in the cell therapy market.

Thermo Fisher Scientific (TMO) has officially introduced the Gibco CTS Compleo system, a cutting-edge automated solution designed for cell therapy manufacturing. This new platform aims to streamline complex production processes, ensuring higher levels of efficiency and consistency in output. The launch serves as a strategic response to the rapidly increasing global demand for advanced cell therapies within the medical sector. By integrating automation, Thermo Fisher seeks to reduce manual errors and lower production costs for biotechnology firms. This expansion of the Gibco portfolio strengthens the company's competitive position in the high-growth biotech industry. Analysts view this move as a positive development for TMO, potentially capturing a larger market share in specialized medical manufacturing.

Create Free Account